What is the recommended dosing, duration, and contraindications for using naproxen to treat an acute gout attack in an adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Naproxen for Acute Gout

For acute gout, start naproxen at 750 mg immediately, followed by 250 mg every 8 hours until the attack resolves, ideally initiated within 36 hours of symptom onset. 1

Dosing Regimen

The FDA-approved dosing for acute gout is specific and straightforward 1:

  • Initial dose: 750 mg naproxen
  • Maintenance: 250 mg every 8 hours
  • Continue until: The acute attack has completely subsided

This regimen is supported by both FDA labeling 1 and clinical trial evidence demonstrating efficacy comparable to other NSAIDs 2, 3. The higher loading dose provides more rapid symptom relief compared to lower initial dosing 4.

Duration of Treatment

Continue naproxen at full dose until the gouty attack has completely resolved 5. Do not taper prematurely—the attack must be fully suppressed before discontinuation. This typically ranges from several days to 1-2 weeks depending on attack severity.

Timing Considerations

Initiate treatment within 36 hours of symptom onset for optimal efficacy 5. Earlier treatment (ideally within 12 hours) produces better outcomes 6. Patients should be educated to self-medicate at the first sign of an attack using a pre-defined treatment plan.

Contraindications and High-Risk Populations

Naproxen is contraindicated or requires extreme caution in patients with 7:

  • Renal disease: Avoid in moderate-to-severe renal impairment (creatinine clearance <30 mL/min) 1
  • Heart failure: NSAIDs can precipitate decompensation
  • Cirrhosis: Increased bleeding risk and fluid retention
  • Active peptic ulcer disease or GI bleeding history: High risk of perforation, ulcers, and bleeding 7
  • Concurrent anticoagulation: Significantly increases bleeding risk

Dose Adjustments

  • Elderly patients: Use lowest effective dose due to increased unbound drug fraction 1
  • Hepatic impairment: Consider dose reduction 1
  • Mild renal impairment: Consider dose reduction, but avoid entirely if CrCl <30 mL/min

Alternative First-Line Options

The 2017 ACP guidelines actually recommend considering corticosteroids as first-line therapy over NSAIDs due to superior safety profile 7. This represents a shift from older guidelines:

  • Prednisolone 35 mg daily for 5 days is equally effective as NSAIDs with fewer adverse events 7, 8, 9
  • Corticosteroids significantly reduce risk of indigestion (RR 0.50), nausea (RR 0.25), and vomiting (RR 0.11) compared to NSAIDs 9
  • Colchicine (1.2 mg then 0.6 mg one hour later) is also first-line if started within 36 hours 5, 7

Clinical Pearls and Pitfalls

Common pitfalls to avoid:

  • Don't use indomethacin preferentially—despite tradition, there is no evidence it's more effective than naproxen or other NSAIDs 7
  • Don't underdose—the 750 mg loading dose is critical for rapid response 1, 4
  • Don't stop too early—continue until complete resolution, not just improvement 5
  • Don't ignore contraindications—NSAIDs cause significant morbidity in high-risk patients; choose corticosteroids instead 7, 9

For patients with multiple comorbidities (renal disease, heart failure, diabetes, hypertension): Strongly consider corticosteroids or colchicine as first-line instead of naproxen 7. The 2017 ACP guidelines emphasize that corticosteroids are "generally safer" with comparable efficacy 7.

Prophylaxis During Urate-Lowering Therapy

If the patient will be starting or is on urate-lowering therapy, low-dose naproxen 250 mg twice daily (with PPI if indicated) can be used for prophylaxis as a second-line option after colchicine 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.